Patients with advanced HPV- and p16INK4a-positive cancers will receive the peptide P16_37-63
in combination with Montanide® ISA-51 VG so that an immune response directed against the
tumor cells can be induced. The aim is to show that vaccination with P16_37-63 is safe and
can induce or enhance immune responses against p16INK4a.